Autolus Therapeutics (AUTL) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts AUTL Hot Sheet
Join SI Premium – FREE
Autolus Therapeutics (NASDAQ: AUTL) reported Q2 EPS of ($0.18), $0.05 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $12.91 million.
For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Assumes Autolus Therapeutics plc (AUTL) at Buy
- Leidos Holdings (LDOS) PT Lowered to $138 at Stifel
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
